Sokhal Ashok Kumar, Sankhwar Satyanarayan, Goel Apul, Singh Kawaljit, Kumar Manoj, Purkait Bimalesh, Saini Durgesh Kumar
Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Urology. 2018 Aug;118:92-97. doi: 10.1016/j.urology.2017.08.025. Epub 2017 Aug 30.
To evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active men who were treated by α1-blockers for benign prostatic hyperplasia and its possible clinical application.
This is a prospective cohort study from January 2015 to December 2016. We enrolled sexually active men above the age of 40 years having moderate to severe lower urinary tract symptoms (LUTS). We excluded patients with a history of prostate surgery, suspicious digital rectal examination findings, a serum prostate-specific antigen of >4 ng/dL, and a history of medication with anticholinergic, cholinergic, and diuretic agents. Patients were divided into groups A, B, and C based on the prescription of silodosin 8 mg, tamsulosin 0.4 mg, or alfuzosin 10 mg orally once for LUTS and at 4 and 12 weeks.
The mean age was 54.8 years (41-68 years). Twelve weeks of treatment with silodosin, tamsulosin, and alfuzosin resulted in a significant improvement in the total International Prostate Symptom Score and the quality of life score (P <.001). The baseline erectile function scores were 26.4, 27.6, and 28.1, and the baseline overall satisfaction (OS) (International Index of Erectile Function [IIEF]-OS) scores were 7.1, 8.3, and 8.6 among groups A, B, and C, respectively. After 12 weeks of α1-blockers, the IIEF-erectile function scores were 24.0, 24.7, and 26.2, and the IIEF-OS scores were 6.4, 7.8, and 7.9. All 3 groups demonstrated a statistically significant enlargement of seminal vesicles after 12 weeks' treatment, most significant in group A patients (7.65-14.11 cc, P <.001).
Alpha-blockers as silodosin, tamsulosin, and alfuzosin are a safe and effective tool in benign prostatic hyperplasia for improving LUTS and the quality of life. Loss of seminal emission with alpha-blockers appears as the cause of seminal vesicle enlargement. The exact mechanism of these findings needs further clinical and experimental research.
评估接受α1受体阻滞剂治疗良性前列腺增生的性活跃男性的性功能障碍和精囊增大情况及其可能的临床应用。
这是一项从2015年1月至2016年12月的前瞻性队列研究。我们纳入了年龄在40岁以上、有中度至重度下尿路症状(LUTS)的性活跃男性。我们排除了有前列腺手术史、直肠指检结果可疑、血清前列腺特异性抗原>4 ng/dL以及有抗胆碱能、胆碱能和利尿剂用药史的患者。根据口服西洛多辛8 mg、坦索罗辛0.4 mg或阿夫唑嗪10 mg治疗LUTS的处方,将患者分为A、B、C组,并在4周和12周时进行观察。
平均年龄为54.8岁(41 - 68岁)。西洛多辛、坦索罗辛和阿夫唑嗪治疗12周后,国际前列腺症状总分和生活质量评分有显著改善(P <.001)。A、B、C组的基线勃起功能评分分别为26.4、27.6和28.1,基线总体满意度(OS)(国际勃起功能指数[IIEF]-OS)评分分别为7.1、8.3和8.6。使用α1受体阻滞剂12周后,IIEF勃起功能评分分别为24.0、24.7和26.2,IIEF-OS评分分别为6.4、7.8和7.9。所有3组在治疗12周后精囊均有统计学意义的增大,A组患者最为显著(7.65 - 14.11 cc,P <.001)。
西洛多辛、坦索罗辛和阿夫唑嗪等α受体阻滞剂是治疗良性前列腺增生、改善LUTS和生活质量的安全有效药物。α受体阻滞剂导致的射精丧失似乎是精囊增大的原因。这些发现的确切机制需要进一步的临床和实验研究。